Showing 2041-2050 of 4307 results for "".
- Poll: People Who Developed AD Symptoms as Kids Experience More Severe Symptomshttps://practicaldermatology.com/news/poll-people-who-developed-ad-symptoms-as-kids-experience-more-severe-symptoms/2460206/Individuals who begin experiencing atopic dermatitis (AD) symptoms as children have vastly different patient journeys and experiences than those who began experiencing symptoms as adults, a new survey from Health Union suggests. Of the survey's 400 respondents, there was a nearly 50
- Phase 3 Study: Aclaris Therapeutics’ A-101 45% May Help Thwart Common Wartshttps://practicaldermatology.com/news/phase-3-study-aclaris-therapeutics-a-101-45-may-help-thwart-common-warts/2460198/Aclaris Therapeutics, Inc.’s A-101 45% Topical Solution (A-101 45%), an investigational new drug, for the potential treatment of common warts, performed well in its second Phase 3 clinical trial, THWART-1 (WART-301). A-101 45% met the primary and all secondary efficacy endpoints,
- UCB’s Bimekizumab Performs Well in Phase 3 Psoriasis Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-phase-3-psoriasis-study/2460186/UCB’s bimekizumab, an IL-17A and IL-17F inhibitor, bested placebo and Stelara (ustekinumab) when it came to clearing the skin of patients with moderate-to-severe chronic plaque psoriasis and improving their symptoms, the company reports. BE VIVID is the first of three Phase 3
- EPI Health Acquires Worldwide Rights to Rhofade from Aclarishttps://practicaldermatology.com/news/epi-health-acquires-worldwide-rights-to-rhofade-from-aclaris/2460180/EPI Health, LLC, has acquired Rhofade (oxymetazoline hydrochloride) cream, 1% and related intellectual property assets from Aclaris Therapeutics, Inc. Rhofade is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. “We are excited ab
- Daily Almond Consumption May Reduce Facial Wrinkleshttps://practicaldermatology.com/news/daily-almond-consumption-may-reduce-facial-wrinkles/2460165/Snacking on almonds may help postmenopausal women smooth wrinkles from the inside out, according to a new study funded by the Almond Board of California. In this 16-week randomized controlled trial, 28 healthy
- Pediatric Dermatologist Who Co-Founded Camp for Children Recognized for Carehttps://practicaldermatology.com/news/pediatric-dermatologist-who-co-founded-camp-for-children-recognized-for-care/2460153/The American Academy of Dermatology honored dermatologist Karen Wiss, MD, FAAD, as a Patient Care Hero for her role in treating a patient with recessive dystrophic epidermolysis bullosa (RDEB). To support pediatric patients with isolating conditions like RDEB, Dr. Wiss, a derm
- L'Oréal USA Announces Winners Of 2019 Women In Digital Next Generation Awardshttps://practicaldermatology.com/news/loreal-usa-announces-winners-of-2019-women-in-digital-next-generation-awards/2460152/L'Oréal USA announced the winners of the 2019 Women in Digital NEXT Generation Awards. The three winners, each of whom will receive $25,000 in grant funding, include Mandi Nyambi and Lanya Olmsted, the co-founders of Baalm, an
- Positive Results for Aclaris Therapeutics’ A-101 45% Topical Solution in Pivotal Phase 3 Trial for the Treatment of Wartshttps://practicaldermatology.com/news/positive-results-for-aclaris-therapeutics-a-101-45-topical-solution-in-pivotal-phase-3-trial-for-the-treatment-of-warts/2460151/Aclaris Therapeutics, Inc., shared positive results from its Phase 3 clinical trial, THWART-2 (WART-302), of A-101 45% Topical Solution, an investigational new drug for the treatment of common warts (verruca vulgaris). A-101 45% Topical Solution met the
- Skin Cancer Foundation Website Has a New Lookhttps://practicaldermatology.com/news/skin-cancer-foundation-website-has-a-new-look/2460148/The Skin Cancer Foundation’s website has a new look. The site is redesigned to ease navigation and provide visitors with an improved user experience. Nearly 9 million people visit SkinCancer.org annually, and the organization say
- Increased Adherence, Symptom Improvement Seen When Psoriasis Patients Switch to IL-17 Blockershttps://practicaldermatology.com/news/increased-adherence-symptom-improvement-seen-when-psoriasis-patients-switch-to-il-17-blockers/2460147/New data points to increased adherence and improvement in symptoms for psoriasis patients who switch to interleukin-17 inhibitors. The study, which was conducted with Walgreens, a parent company of AllianceRx Walgreens Prime, was presented at the National Association of Specialty Pharma